Skip to main content
logo
Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.580
-0.060 (-2.27%)
At close: Aug 28, 2026, 4:00 PM EDT
2.680
+0.100 (3.88%)
After-hours: Aug 28, 2026, 7:52 PM EDT

Atossa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
18.0515.9613.514.0412.6111.31
Research & Development
21.221.1914.1217.3315.089.21
Operating Expenses
39.2537.1427.6231.3827.6920.52
Operating Income
-39.25-37.14-27.62-31.38-27.69-20.52
Interest & Investment Income
1.552.384.054.340.880.01
Other Non Operating Income (Expenses)
-0.01-0.01-0.22-0.07-0.15-0.09
EBT Excluding Unusual Items
-37.71-34.77-23.79-27.1-26.96-20.61
Gain (Loss) on Sale of Investments
---1.71-2.99--
Pretax Income
-37.71-34.77-25.5-30.09-26.96-20.61
Earnings From Continuing Operations
-37.71-34.77-25.5-30.09-26.96-20.61
Net Income
-37.71-34.77-25.5-30.09-26.96-20.61
Net Income to Common
-37.71-34.77-25.5-30.09-26.96-20.61
Net Income Growth
------
Shares Outstanding (Basic)
998888
Shares Outstanding (Diluted)
998888
Shares Change
1.95%2.63%-0.18%-0.43%8.27%934.13%
EPS (Basic)
-4.34-4.04-3.04-3.58-3.19-2.64
EPS (Diluted)
-4.34-4.04-3.04-3.58-3.19-2.64
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-35.78-29.79-21.05-20.96-20.79-16.48
Free Cash Flow Per Share
-4.12-3.46-2.51-2.49-2.46-2.11
EBITDA
-39.24-37.13-27.6-31.35-27.68-20.5
D&A For EBITDA
0.020.020.020.020.010.02
EBIT
-39.25-37.14-27.62-31.38-27.69-20.52
SEC Filings: 10-K · 10-Q